Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.
Deregulating New Zealand's gene tech space has been long-desired, but critics say the Government's growth-focused approach ...
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a ...
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says the company is the “pioneer of gene editing” and ...
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...
In addition, first-generation CRISPR systems (Cas9 and Cas12a) are too large for efficient in vivo delivery via a single adeno-associated viral (AAV) vector. Now, new preclinical research ...
The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...